---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-121456"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:22:32.658282+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Treace Medical Q3 revenue $45.1M (+11%), net loss improves to ($15.4M), launches Nanoplasty MIS system

## Summary
- Revenue $45.1M (+11% YoY); net loss improved to ($15.4M) or ($0.25)/share from ($17.5M) loss in Q3 2023.
- Adjusted EBITDA loss narrowed 45% to ($5.1M) from ($9.2M) in Q3 2023.
- First entry into osteotomy market with Nanoplasty 3D Minimally Invasive Bunion Correction system; second MIS platform planned later in Q4.
- Filed patent infringement suit to protect Lapiplasty technology; patent portfolio now 67 U.S. patents.
- FY2024 revenue guidance revised to $204M-$211M (was $201M-$211M); expects Adjusted EBITDA loss to halve YoY.

## SEC filing metadata
- accession: 0000950170-24-121456
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017024121456/0000950170-24-121456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017024121456/tmci-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-121456
- JSON: https://secwatch.observer/filing/0000950170-24-121456.json
- Plain text: https://secwatch.observer/filing/0000950170-24-121456.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.